Atai Life Sciences (ATAI) said Tuesday that topline data from a phase 2a trial showed that a single dose of its drug BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, produced antidepressive effects of up to three months.
The drug was well-tolerated with no serious adverse events, and an average in-clinic treatment time following dosing of less than two hours, the company said.
The 12-patient study showed average MADRS score reductions of 18 to 19 points up to three months post-treatment, supporting prior monotherapy findings, Atai said.
Atai shares were 3.8% lower in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。